Netherlands· NL-d3b9de6b1d31
Zykadia 150 mg, filmomhulde tablet
A ceritinib product containing ceritinib, registered in Netherlands by Novartis Europharm Limited. The same ATC class is registered in 13 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Ceritinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01ED02 (ceritinib), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Ceritinib · ATC L01ED02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ceritinib costs, country by country.
Normalised to the WHO defined daily dose (0.45 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ceritinib · price per daily dose (0.45 g)
USD · FX 28 Sept 2026
- CH Switzerland$188.22
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CERITINIB
- Manufacturer
- Novartis Europharm Limited
- Country
- Netherlands (NL)
- ATC code
- L01ED02
- ATC class
- Ceritinib
- Defined daily dose
- 0.45 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/15/999
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
769 interactions on record for ceritinib.
Graded by severity as the source publishes them — 449 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ceritinib · interactions on record
769 records
- 449 severe
- 307 moderate
- 13 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ceritinib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumZykadia 150 mgNovartis Europharm
- SwitzerlandZykadia, FilmtablettenNovartis Pharma Schweiz AG
- CzechiaZYKADIANovartis Europharm Limited, Dublin
- FinlandZykadiaNovartis Europharm Limited
- IrelandZykadia 150 mg film-coated tabletNovartis Europharm Limited
- IcelandZykadiaNovartis Europharm Limited*
- NorwayZykadiaNovartis Europharm Limited (1)
- PolandZykadiaNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zykadia
- Liechtenstein · Zykadia
- Norway · Zykadia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9cfacd85-a551-46f0-9ee7-3d17a2b74cc7 GET /v1/drugs/9cfacd85-a551-46f0-9ee7-3d17a2b74cc7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Ceritinib",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp123186",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"HYDROXYPROPYLCELLULOSE, LAAG GESUBSTITUEERD (E 463a)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"INDIGOKARMIJN ALUMINIUMLAK (E 132)",
"MACROGOL 4000",
"MAGNESIUMSTEARAAT (E 470b)",
"POVIDON K 30 (E 1201)",
"SILICIUMDIOXIDE (E 551)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"CERITINIB"
],
"leaflet_url": null,
"authorised_at": "2019/04/02",
"procedure_number": "EMEA/H/C/003819",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/15/999",
"additional_monitoring": "N"
}See everything about ceritinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.